Acute lymphoblastic leukemia (ALL) is the most common hematological cancer in children. The complex genetic landscape of ALL is being unraveled by the availability of new –omic tools, pointing to an extensive network of altered pathways sustained by dysregulated micro-environmental signals. The identification of recurrent somatic chromosomal translocations and somatic mutations by novel diagnostic techniques (such as next-generation sequencing or optical genome mapping) has allowed the proposal of new genetic risk classifications, which complement minimal residual disease to select very high and very low-risk patients. They also identify candidates for targeted therapies, which combined with CAR-T-cells therapy and immunotherapy supposes a survival chance to very poor-risk patients.
Although our knowledge of ALL has expanded exponentially in the last few years, there are still issues that remain elusive. The goal of this Research Topic is to shed light on the molecular biology of ALL by:
- The identification and impact of novel germ-line variants is an evolving field that must be expanded
- Comprehensive research integrating clinical and molecular data using artificial intelligence can identify disease subgroups that can benefit from tailored treatments
- The development of new diagnostic tools may help prevent or anticipate disease onset or relapse
The scope of this Research Topic includes any original research focusing on molecular aspects of Acute lymphoblastic leukemia that may help understand this disease.
Acute lymphoblastic leukemia (ALL) is the most common hematological cancer in children. The complex genetic landscape of ALL is being unraveled by the availability of new –omic tools, pointing to an extensive network of altered pathways sustained by dysregulated micro-environmental signals. The identification of recurrent somatic chromosomal translocations and somatic mutations by novel diagnostic techniques (such as next-generation sequencing or optical genome mapping) has allowed the proposal of new genetic risk classifications, which complement minimal residual disease to select very high and very low-risk patients. They also identify candidates for targeted therapies, which combined with CAR-T-cells therapy and immunotherapy supposes a survival chance to very poor-risk patients.
Although our knowledge of ALL has expanded exponentially in the last few years, there are still issues that remain elusive. The goal of this Research Topic is to shed light on the molecular biology of ALL by:
- The identification and impact of novel germ-line variants is an evolving field that must be expanded
- Comprehensive research integrating clinical and molecular data using artificial intelligence can identify disease subgroups that can benefit from tailored treatments
- The development of new diagnostic tools may help prevent or anticipate disease onset or relapse
The scope of this Research Topic includes any original research focusing on molecular aspects of Acute lymphoblastic leukemia that may help understand this disease.